Carlyle Group Inc.
Institutional investor · Portfolio as of Q2 2021
Top Holdings10 positions
Stock | Shares | Value | Weight | Avg Buy | Est. P&L | Held | Conviction |
|---|---|---|---|---|---|---|---|
ZOOMINFO TECHNOLOGIES INC | 88.3M | $4.6B | 31.2% | $50.72 | +5.34% | 5 qtrssince 2020-Q2 | Decreased 0 |
ATOTECH LTD | 153.7M | $3.9B | 26.5% | — | — | 2 qtrssince 2021-Q1 | Unchanged 0 |
ORTHO CLINICAL DIAGNOSTICS H | 143.4M | $3.1B | 20.8% | — | — | 2 qtrssince 2021-Q1 | Unchanged 0 |
PPD INC | 55.7M | $2.6B | 17.4% | — | — | 6 qtrssince 2020-Q1 | Unchanged 0 |
1LIFE HEALTHCARE INC COM | 13.6M | $450M | 3.0% | — | — | 6 qtrssince 2020-Q1 | Unchanged 0 |
VITRU LTD | 6.2M | $107.4M | 0.7% | — | — | 4 qtrssince 2020-Q3 | Unchanged 0 |
TALOS ENERGY INC | 2.3M | $36.4M | 0.2% | $5.70 | +175.09% | 6 qtrssince 2020-Q1 | Decreased 0 |
| 7.9M | $9.7M | 0.1% | — | — | 11 qtrssince 2018-Q4 | Unchanged 0 | |
SEACOR MARINE HLDGS INC | 1.1M | $5.1M | 0.0% | $11.28 | -61.00% | 11 qtrssince 2018-Q4 | Unchanged 0 |
SIRIUSPOINT LTD | 129,408 | $1.3M | 0.0% | $10.29 | -0.97% | 2 qtrssince 2021-Q1 | Unchanged 0 |
Carlyle Group Inc. manages $14.8B across 10 positions as of Q2 2021. Top holdings: GTM (31.2%), ATC (26.5%), OCDX (20.8%). Fund DNA: Concentrated Value. HoldingsIntel Rating: 1.5/5.0.
Exited 2, trimmed 2. No standout high-conviction moves this quarter. Portfolio: $14.8B across 10 positions.
Top holdings by portfolio weight
Portfolio allocation by GICS sector
Behavioral investing profile
Position Outcomes
Best and worst performing positions by estimated return
Top Winners
Top Losers
Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.
Similar Funds
Funds with similar investing DNA
Explore More
Accumulation Streaks
Positions with 2+ consecutive quarters of increases - persistent directional conviction.
No active accumulation streaks detected for this filer.
Streaks require 2+ consecutive quarters of increased positions in the most recent period.
Continue exploring
Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer